SARS_CoV_2 mutation literature information.


  Synthetic proteins for COVID-19 diagnostics.
 PMID: 34087220       2021       Peptides
Abstract: Variants of JS7, such as E484K or N501Y, can be quickly synthesized in pure form in large quantities by automated methods.
Figure: Three circulating human variants in the JS7 sequence, L452R (recent California), E484K and N501Y are indicated by red arrows, yellow side chains in the structure above.
Discussion: Although the N501Y mutant did not alter neutralization by polyclonal antibodies in some test sera, other changes in this area at the interface of the RBD and its ACE2 receptor.


  Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.
 PMID: 34097716       2021       PLoS pathogens
Introduction: The hallmark mutation shared by the B.1.1.7, B.1.351, and P.1 lineages is N501Y, located in the receptor-binding domain (RBD) of the spike protein.
Result: We previously identified P.1 lineage SARS-CoV-2, which harbors the K417T/E484K/N501Y mutations, in one patient.


  Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
 PMID: 34098567       2021       Nature
Introduction: A second variant of concern is B.1.351, which combines N501Y with two additional RBD substitutions (K417N and E484K).
Introduction: In contrast to their efficacy against the wild-type virus, Nb17, Nb19 and Nb56 were unable to neutralize viruses carrying the E484K substitution alone or in combination with K417N and N501Y.
Introduction: Of particular interest is t


  Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review.
 PMID: 34103090       2021       European journal of medical research
Table: N501Y


  V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
 PMID: 34105996       2021       Journal of virology
Discussion: For example, through deep mutation scanning, an assumed N501F mutation was confirmed to have enhanced binding efficiency while not emergent, but later, the N501Y mutation in the same position with a similar enhancing effect was frequently detected in emerging lineage B1.1.7 variants.


  FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip.
 PMID: 34106048       2021       eLife
Abstract: We report the detection of the S gene mutation N501Y (present across multiple variant lineages of SARS-CoV-2) within an hour using lateral flow paper strip chemistry.
Introduction: RAY can successfully detect both SARS-CoV-2 infection as well as the presence of the common N501Y mutation present across the majority of VOCs described so far and distinguish it from the parent CoV2 lineage.
Method: A region from the SARS-CoV-2 S gene containing N501Y/T716I/E484K mutations was reverse transcribed and amplified using a single end 5' biotin-labeled primer.


  SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection.
 PMID: 34109031       2021       Annals of medicine and surgery (2012)
Abstract: The essential modifications located in the spike glycoprotein RBD include E484K, K417T and N501Y.
Introduction: One of the significant mutations in N501Y was noted in RBD.
Introduction: The essential mutations in the spike include the glycoprotein RBD, E484K, K417T, and N501Y.


  SARS-CoV2 spike protein gene variants with N501T and G142D mutation-dominated infections in mink in the United States.
 PMID: 34109885       2021       Journal of veterinary diagnostic investigation
Introduction: Comparatively, the incidence of N501Y is much lower in the United States and Canada than globally.
Introduction: However, it cannot be ruled out that the different time of introduction of N501Y and N501T (April 2020 vs.
Introduction: In the GISAID (Global Initiative on Sharing All Influenza Data, https://www.gisaid.org) database of SARS-CoV2 genomes as of March 17, 2021, 758,684 of 792,388 (95.7%) of the SARS-CoV2 genome had the D614G mutation in the S protein gene; and 178,186 of 792,388 (22%) had the N501Y mutation, which occurred in the more virulent U.K.


  Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
 PMID: 34119826       2021       Biochemical and biophysical research communications
Introduction: For instance, the B.1.1.7 (501Y.V1) variant first described in the UK, and containing a N501Y mutation in the spike protein has spread to more than 100 countries worldwide.
Introduction: In contrast, LY-CoV555 showed preserved activity against the UK variant but activity against the SA variant was completely abolished since LY-CoV555 cannot bind to triple mutant protein (K417N/E484K/N501Y) of RBD in SARS-CoV-2 SA variant.
Introduction: The second variant of concern (VOC), B.1.351 (501Y.V2) first discovered in South Africa variant, has 9 mutations (L18F, D80A, D215G, Delta242-244, K417N, E484K<


  Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.
 PMID: 34120577       2021       Emerging microbes & infections
Method: Briefly, 96-well microtiter plates (Corning, Cat no: 9018) were coated with 100 muL of 1 mug/mL ectodomain of spike protein (ECD), S1 protein, RBD protein, RBD variants protein (RBD E484K, RBD K417N, RBD N501Y, RBD N501Y/K417N/E484K), in coating buffer (pH 9.6) overnight at 4 C, respectively.
Method: Recombinant SARS-CoV-2 ECD protein (Genscript, Cat no: Z03481) and the related RBD variants (RBD N5



Browser Board

 Co-occurred Entities




   Filtrator